TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Radiopharm Theranostics Limited ( (AU:RAD) ).
Radiopharm Theranostics Limited has received IND approval from the FDA to begin a Phase I clinical study targeting B7H3 with Betabart, and has appointed Dr. Oliver Sartor to its Scientific Advisory Board. The company also announced positive updates across four clinical programs, with significant milestones expected in 2026, and secured a A$35 million institutional placement to support ongoing initiatives. The RAD 101 Phase 2b imaging study showed promising results in targeting brain metastases, while the RAD 202 Phase 1 ‘HEAT’ trial demonstrated higher-than-expected tumor uptake, supporting its potential as a novel HER2-directed radiotherapeutic.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a developer of radiopharmaceutical products, focusing on both diagnostic and therapeutic applications. The company is involved in creating a world-class platform for these products, with a market focus on innovative solutions for cancer treatment and diagnosis.
Average Trading Volume: 6,090,118
Technical Sentiment Signal: Buy
Current Market Cap: A$72.3M
See more insights into RAD stock on TipRanks’ Stock Analysis page.